

## CURRENT REPORT

Report date: **21.05.2026**

Name of issuing company: **Antibiotice S.A.**

Headquarters: **lași, str. Valea Lupului nr. 1, zip code 707410**

**<https://www.antibiotice.ro>**

E-mail: **[relatiicuinvestitorii@antibiotice.ro](mailto:relatiicuinvestitorii@antibiotice.ro)**

Telephone/fax no. : **+40232 209 000 / +40372 065 633**

Unique registration code in the Trade Register Office: **RO1973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804 LEI**

The regulated market trading on which the securities are issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 lei**

### **Antibiotice SA is accelerating its strategic investments through a 67 million euro financing facility granted by Banca Transilvania**

Antibiotice SA continues to develop several strategic projects for the pharmaceutical industry through a 67 million in funding granted by Banca Transilvania. The investment supports the implementation of two key projects aimed at strengthening the company's production and innovation capabilities:

- **"Production, packaging, storage capacity for sterile products, solutions and topicals"** - is one of the most important investment projects developed by Antibiotice lași in recent years. By this investment, our company strengthens its strategic position in the topicals and sterile solutions segments, both domestically and internationally, by diversifying the essential medicine portfolio used in hospitals. The project contributes to increasing the resilience of the healthcare system and ensuring the availability of essential therapeutic solutions, with a direct impact on saving people's lives. The project has started with funding from the European Investment Bank in Romania through the InvestEU program and also benefits from non-reimbursable funds granted by the Ministry of Finance.
- **INOVA Research & Development Center+ and the new production site for critical medicines** represents a strategic investment, with a major impact on the health security of Romania and Europe. The project contributes to strengthening Romania's capacity to produce critical medicines locally, reducing dependence on external

supply chains and supporting the European Union's objectives regarding strategic autonomy in the field of health. This investment strengthens the Antibiotice's long-term growth prospects by developing innovation capabilities, expanding its product portfolio and increasing competitiveness on international markets. The project also includes a non-reimbursable funding component provided by the Ministry of Investments and European Projects, through the STEP (Strategic Technologies for Europe Platform) program.

*„This financing strengthens the capacity of Antibiotice Iași to accelerate strategic investments and support long-term growth objectives, both in the Romanian market and internationally. Our partnership with the Banca Transilvania reflects confidence in our development direction and in the company's potential to generate sustainable value for the healthcare system, partners and shareholders”* declared Mr. Ioan Nani, General Director of Antibiotice SA.

The financing marks a new stage in the collaboration between the two companies and supports the implementation of investments with strategic impact for the pharmaceutical industry in Romania.

*”We are honored to support the Antibiotice's development plans by financing strategic projects both for the company and for the entire Romanian medical ecosystem. This financing reconfirms the Banca Transilvania's commitment to supporting champion companies in Romania, which generate value, innovation and impact in people's lives.”* - declared Cosmin Călin, Senior Executive Director - Large Companies, Structured Finance and Factoring, Banca Transilvania.

Both Banca Transilvania and Antibiotice are part of the BET index of the Bucharest Stock Exchange, which brings together the 20 most traded companies listed on the BVB. The collaboration between the banking and pharmaceutical sectors, through financing such as the one announced today, accelerates investments in a strategic field for Romania, with a multiplier effect in the economy and the healthcare system.

## **General information**

### **BANCA TRANSILVANIA**

Banca Transilvania (BVB: TLV) is the largest financial player in Romania and Southeastern Europe, a digital banking ecosystem that connects millions of people and businesses to financial solutions. As a universal bank, BT covers all customer segments and all business lines. BT has a 23% market share, 5 million customers, 72,000 shareholders & investors and over 10,000 employees. The national network,

consisting of 530 branches, together with state-of-the-art digital platforms, ensures access to banking services from anywhere and anytime.

## **ANTIBIOTICE SA**

Antibiotice Iași (BVB: ATB) is the largest pharmaceutical manufacturer with majority Romanian capital, with over 70 years of expertise in the development of generic medicines aligned with international standards and a presence in over 50 countries. The company has maintained its position as a world leader in the production of the active substance Nystatin for over a decade, and since 2017, Nystatin produced by Antibiotice has been recognized by the United States Pharmacopeia as an international reference quality standard. Antibiotice SA integrates also the principles of sustainability in all its activities, through the responsible use of resources and the reduction of environmental impact, supporting long-term sustainable development.

General Director,  
*Ioan NANI, Economist*